Page 11 - Read Online

Baker et al. J Cancer Metastasis Treat 2020;6:24 I http://dx.doi.org/10.20517/2394-4722.2020.36 Page 7 of 12

Figure 1. Types (top panel) and numbers (bottom panel) of risk factors identified prior to enrollment by patient, grouped by age at
baseline. Note: except for body mass index (BMI) and high-sensitivity C-reactive protein (hsCRP), these are distinct from, and derived
using different data than, the baseline laboratory measurements

of sarcoma survivors treated with moderate dosing of anthracyclines confirms the presence of multiple
CAD risk factors, beyond what would be expected in a healthy population, particularly so for patients
younger than 40. The presence of these chronic conditions demonstrates the need for active prevention and
management of late effects, in addition to monitoring for relapse. This clinic was piloted solely for survivors
of bone and soft tissue sarcomas treated with anthracycline chemotherapies.

Patients are educated about their risks of developing chronic conditions as a consequence of their sarcoma
treatment. Our patients are counseled on behavioral and lifestyle approaches to reduce these risks, and
referred to needed medical services such as psycho-oncology when available or a social worker, nutritional
counseling, and physical medicine to decrease pain and improve mobility (especially for those who have
had limb salvage surgery). Patients who present with a systolic blood pressure > 130 are urged to obtain a
home blood pressure cuff and taught to take measurements in accordance with best practices (twice in the
morning). Patients are encouraged to report their blood pressure readings electronically with the provider
to accurately assess their blood pressure in acknowledgement that some patients experience transient